毅德國際(01396.HK):要約截止 5.92億股獲有效接納
格隆匯10月11日丨毅德國際(01396.HK)公佈,有關獲鴻隆創始人曾雲樞等折讓三成提全購事宜,股份要約已於2019年10月11日(星期五)下午4:00時截止及並無修訂或延期。
於2019年10月11日(星期五)下午4:00時,要約人已接獲根據股份要約就合共5.92億股要約股份的有效接納,佔於公告日期公司全部已發行股本約14.74%。
於緊接股份要約截止後及於公告日期,待過户登記處正式登記已接獲有效接納之要約股份之過户,10.53億股股份(佔公司全部已發行股本約26.23%)由公眾人士持有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.